Abstract
The global healthcare landscape id deeply influenced by Intellectual Property Rights (IPR), especially patents, which grant exclusive monopoly over life-saving drugs. While IPRs serve to incentivize innovation, it often creates a stark inequity, particularly in low and middle-income countries where the burden of disease is high but access to essential medicines remains limited. This research critically examines how IPRs contribute to the widening health divide, focusing on the impact of the TRIPS Agreement, Patent Evergreening, and the Role of Pharmaceutical Corporations in balancing innovation with the right to health. The study will also explore real-world cases where rigid patent protection has restricted or enabled access to essential drugs concluding with recommendations and legal reforms to bridge the health gap without discouraging pharmaceutical advancements.
Keywords: Intellectual Property Rights, TRIPS, Patent, Patent Evergreening, Health Divide, Access to Medicines.
Introduction
The intersection of Intellectual Property Rights (IPR) and healthcare has been the subject of global debate for a long time. At the heart of this issue, the fundamental question lies: should life-saving medicines be treated as private commodities or be global public goods? The existing patenting regime, particularly in the pharmaceutical sector, often tips this balance in the favour of commercial interest rather than public interests. Patents grant pharmaceutical companies a 20-year monopoly on their innovation, allowing them to recover research and development (R&D) costs. However, this exclusivity frequently results in exorbitant drug pricing, making essential medicines inaccessible to vast populations, particularly low and middle-income countries. The TRIPS Agreement, 1955 on Trade Related Aspects of Intellectual Property Rights further strengthened patent protection worldwide. While its intent was to harmonise intellectual property laws and spur innovation, it inadvertently exacerbated global health inequities. Diseases such as HIV/AIDS, TB, Cancer remain prevalent in poorer nations, yet the high costs of patented drugs keeps treatment out of the reach for millions of people. This situation is worsened by practices like patent evergreening, where minor modifications to the existing drug formula is done and the monopoly is extended without substantial innovation. Recognising the adverse impact of the rigid patent protection, the World Trade Organisation (WTO) introduced TRIPS flexibilities, allowing mechanisms like compulsory licensing to improve medicine access during health crises like COVID-19. This paper seeks to analyse the role of IPR in perpetuating the health divide, assess the implementation pf TRIPS flexibilities, and explore policy alternatives. By balancing patent rights with public health imperatives, a more equitable global healthcare system can be envisioned- one where access to essential medicines is not determined by wealth but by need.
Short Statement of the Problem
The primary concern this research seeks is to address the growing disparity in global health outcomes due to the monopolistic nature of the pharmaceutical patents protected under IPRs. While they are designed and developed to encourage innovation, IPR often leads to unaffordability and inaccessibility of life-saving drugs in smaller and poorer countries. High costs driven by patents create a significant barrier to accessing essential drugs, worsening the existing health divide between the rich and the poor nations.
The TRIPS Agreement and subsequent TRIPS-plus agreements have further complicated this scenario, limiting the capacity of low- and middle-income countries to safeguard health.
Reseach Objectives
The primary objectives of the research are:
- To analyse the impact of IPRs, especially patent protections, on the availability and affordability of essential medicines.
- To evaluate the effectiveness of international legal frameworks like TRIPS and the Doha Declaration in ensuring access to medicines.
- To suggest policy recommendations for bridging the existing health divide while preserving incentives for pharmaceutical innovations.
Research Questions
- How do IPRs influence the access to essential medicines in low and middle-income countries?
- What are the limitations of the TRIPS Agreement and TRIPS-plus provisions in ensuring equitable access to drugs?
- How effective are the mechanisms like compulsory licensing in addressing public health emergencies?
- What reforms or global cooperative efforts can balance patent rights with the rights to health?
Research Hypothesis
While IPR foster pharmaceutical innovation, their rigid enforcements, particularly through patent monopolies, significantly restrict access to essential medicines in low and middle-income countries, thereby widening the global health gap.
Research Methodology
This research adopts a qualitative and a doctrinal methodology, focusing on the analysis of international treaties, conventions and declarations.
Literature Review
The relation between IPR and access to essential medicines has been a long-contested issue in the global health discourse, scholars argue that while patents are crucial to incentivise pharmaceutical research and development, they often hinder the accessibility of life-saving saving meds in low and middle-income countries. The most significant legal framework shaping this dynamic is the WTO’s TRIPS, 1955. TRIPS mandated a minimum of 20 years of patent protection, extending monopoly rights to pharma companies worldwide. Then later, the WTO introduced the Doha Declaration on TRIPS and public Health (2001) which reaffirmed countries’ rights to prioritize public health over patent rights. It allowed measures like compulsory licensing and parallel imports to improve drug access. However, scholars like Frederick Abbott argue that these flexibilities remain underutilized due to political pressure, lack of technical expertise and fear of retaliation from developed nations and pharma corporations.
One persistent concern within the patent system is the ‘evergreening’- a strategy where pharma companies make minor, non-therapeutic changes to the drug formula to extend their patent life hence monopoly over the drug supply in the market. Tahir Amin critiques this practice, noting it blocks generic manufacturers from producing affordable versions of the drug, thereby delaying market competition.
Countries like India have addressed this through Section 3(d) of their Patent Act, setting a global precedent by rejecting patents based solely on trivial modifications.
Overall, the literature paints a complex picture: while IPR is vital for innovation, its current nt structure perpetuates inequities, there is an urgent need for recalibrated policies that balance innovation incentives with public health obligations, ensuring essential medicines are universally accessible.
Key References:
- Abbott, F. (2005). The Doha Declaration on the TRIPS Agreement and Public Health.
- Amin, T. Evergreening of Patents and TRIPS Agreement
IPRs significantly influence medicine accessibility, the enforcements of patent laws under the TRIPS Agreement has led to a steep rise in medicine prices, making loife-saving drugs unaffordable for millions, particularly in low and middle-income countries. The health gap is visible in stark disparities in access to HIV drugs, Cancer treatments, insulin, TB etc.
TRIPS flexibilities remain underutilized, while the Doha Declaration allows countries to issue compulsory licenses and undertake parallel imports, most developing nations use these mechanisms. Fear of trade sanction, complex legal procedures, and diplomatic pressures deter countries from invoking these rights.
Evergreening worsens the health divide, pharmaceutical companies exploit patent law loopholes through evergreening, extending their monopoly with insignificant changes to the grug or its formula. This practice delays the entry of affordable, generic, prolonging patient suffering and widening inequality in healthcare access.
Access to essential medicines is a human rights issue, the denial of affordable medicines violate the fundamental right to health, as recognised under international law. The IPR regime, as it currently operates, prioritizes corporate profits over human lives, especially in vulnerable regions.
India’s patent law model offers a balanced approach. India’s Section 3(d) of the Patent Act and its landmark compulsory licensing case Natco Pharma vs Bayer demonstrates a workable model balancing IPR and public health divide.
Analysis
The intricate relationship between IPR and public health divide reflects a deep-rooted conflict between promoting pharmaceutical innovation and ensuring equitable healthcare access. At its core, the patent system was designed to reward innovation by granting temporary monopolies. However, when it comes to essential medicines, this model often creates more harm than good for vulnerable populations.
Patents undeniably create artificial scarcity by granting pharmaceutical companies exclusive rights over life-saving drugs, this leads to exorbitant drug pricing, making essential medicines inaccessible to vast populations, particularly low and middle-income countries for diseases like HIV/AIDS, TB, Malaria, Cancer etc. Such places bear financial burden which further widens the global health divide.
The TRIPS Agreement, while standardized globally, did not initially consider the public health realities of the developing world. The Doha Declaration attempted to correct this by allowing flexibilities like compulsory licensing, however, the execution has been poor. Countries either lack the resources or the political will to utilize these provisions. Developed nations often exert diplomatic or economic pressure to discourage such moves, preserving profits for their pharmaceutical sectors.
For instance, when Thailand granted obligatory licenses for anti-HIV and heart disease medications, it became the target of criticism from some Western countries as well as multinational drug companies. These events display how the uneven power dynamic tramples on the essence of the Doha Declaration.
The Role of Global Pharmaceutical Giants
Large pharma corporations contend that patents are essential to recoup the enormous R&D costs. Nevertheless, it is shown that considerable amount public investment frequently goes into the early research on many of the blockbuster drugs. Nevertheless, patented, these drugs are sold at prices inaccessible to millions of people. Moreover, strong-arm lobbying by these corporations has promoted TRIPS-plus agreements, which add even higher IP restrictions, further restricting developing nations’ access.
Human Rights Approach: Redefining the Debate
Using access to medicines as a human rights question presents a moral and legal counter-narrative to the ascendancy of patent regimes. Global covenants such as the International Covenant on Economic, Social and Cultural Rights (ICESCR) acknowledge the right to health, including access to medicines. This positioning turns the debate away from the market-driven model towards one asking states and corporations to be accountable for the health and life of millions.
(International Covenant on Economic, Social and Cultural Rights (ICESCR)
Published: 28 October 2019)
India’s Balancing Act: A Model for Others
India’s strategy, especially with Section 3(d) of the Patent Act, is frequently brought up as an example. By refusing to grant patents over minor changes, India guarantees the availability of generics in the marketplace earlier. India’s compulsory licensing in the Natco-Bayer case is the quintessential instance where public health was preserved and yet the innovation incentive was not destroyed. Such legal policies demonstrate that nations can—and need to—harness public health without totally killing the incentive for innovation.
RECOMMENDATIONS
A number of measures can be implemented at both the national and global levels to close the health gap and provide fair access to necessary medicines while striking a balance between Intellectual Property Rights (IPR):
1. Strengthen Use of TRIPS Flexibilities
Developing countries and other nations should be incentivized and facilitated to make effective use of the TRIPS flexibilities like compulsory licensing, parallel imports, and patent oppositions. This will call for building legal capacity, diplomatic support, and technical help so that these tools are not merely on paper but real options.
Example: Countries can adopt India’s strategy where compulsory licensing has been used effectively to reduce the cost of Nexavar in cancer treatment.
2. Prevent Patent Evergreening
National laws must be strengthened to prevent issuing patents for small modifications to old drugs without real therapeutic innovations. Nations may incorporate clauses like Section 3(d) of India’s Patent Act to screen out spurious patents.
Effect: This bars monopolies from being extended unfairly and permits generics to reach the market sooner, lowering costs and improving access.
3. Encourage Generic Competition
Manufacturing generic drugs continues to be the best solution to cut costs and expand access. Governments need to incentivize domestic pharmaceutical companies to invest in producing generic copies of key medicines, particularly for those diseases that disproportionately impact their population.
WHO estimates: Generic competition lowers prices by 70-90% in the majority of cases after exclusivity ends.
4. Global Fund and International Pooling Mechanisms
Global mechanisms such as the Medicines Patent Pool (MPP) and Global Fund for HIV/AIDS, Tuberculosis, and Malaria need to be scaled up. These arrangements facilitate voluntary licensing of patents under which prices become lower while allowing some royalties for patent owners.
Example: MPP was successful in negotiating the price of antiretrovirals and Hepatitis C medicines at lower costs in most LMICs.
5. Empower Access to Medicines as a Human Right
Governments have to legally establish access to vital medicines as an integral part of the right to health, as guaranteed in international covenants. This will compel countries to put health above commercial interests and pharmaceutical lobbying when making policies.
UN Special Rapporteur (2023): “Access to medicines is a core component of the human right to health.”
6. International Cooperation and South-South Partnerships
Developing nations must have more cooperation among themselves—legal strategies, manufacturing capabilities, and combined procurement systems to negotiate improved prices from drug companies.
Example: The African Medicines Agency (AMA) is a move towards regional regulation of pharmaceuticals and combined procurement.
7. More Transparency in R&D Costs
Pharmaceutical companies should be required to publish the true R&D expenses behind new drugs. This will help control the price determination and reveal inflated pricing masquerading under the euphemism of “innovation costs.”
CONCLUSION
The nexus of Intellectual Property Rights and access to medicines is one of the most daunting ethical, legal, and public health dilemmas of our day. Although the patent regime under TRIPS was intended to stimulate innovation, its strict enforcement has been a mainstay of the current global health gap. Millions of individuals in low- and middle-income countries remain deprived of life-saving medicine merely because patented medicines continue to be priced out of their reach.
Even with the advent of the Doha Declaration and TRIPS flexibilities, most countries—particularly those that are not economically and politically powerful—find it difficult to harness these provisions efficiently. The pharmaceutical corporations’ increasing power and patent evergreening make the situation worse by prolonging the monopoly at the cost of human lives.
But there are solutions. The Indian model, striking a balance between patent protection and public health safeguards, is a model that can be emulated by other countries. Global mechanisms such as the Medicines Patent Pool and compulsory licensing can fill the gap, if there were more political will and international coordination.
Finally, access to medicines has to be seen not only as a policy issue but as a human right. Public health should never be offered up at the altar of profit for corporations. While global gaps in access to healthcare continue to grow, it is essential that policymakers, international institutions, and civil society organizations unite to develop a system in which human life and innovation coexist such that medicines that are essential are affordable and available to all.
Links Used
- Carlos M Correa, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (Zed Books 2000).
- United Nations, International Covenant on Economic, Social and Cultural Rights (1966) https://www.ohchr.org/en/instruments-mechanisms/instruments/international-covenant-economic-social-and-cultural-rights
- Doha WTO Ministerial, Declaration on the TRIPS Agreement and Public Health (2001) WT/MIN(01)/DEC/2 https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm
- Natco Pharma Ltd v Bayer Corporation (Compulsory License) [2012] Controller of Patents (India) https://spicyip.com/2012/03/natco-wins-compulsory-license-battle.html
- UN Special Rapporteur on the Right to Health, Report on Access to Medicines (UN Human Rights Council 2023) https://www.ohchr.org/en/issues/health/pages/srrighthealthindex.aspx
NAME: HONEY SONI
COLLEGE: NMIMS Kirit P. Mehta School of Law, Mumbai
COURSE: BA.LLB, Hons.